Billerica, Massachusetts —May 19, 2010—Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life science industry, has moved its European BioPharma Services unit to new, expanded facilities to accommodate strong growth in the biotechnology sector. The new facilities are located in Milton Park, near Didcot in Oxfordshire, England.
Millipore’s BioPharma Services unit is the first global contract research organization (CRO) dedicated exclusively to large molecule bioanalytical work. The unit arose from Millipore’s acquisition in August, 2009 of BioAnaLab, an Oxford University spin-out, specializing in the analysis of biopharmaceuticals.
Geoff Hale, Managing Director of BioAnaLab said: “The new laboratory provides us with space to continue our growth as we expand the range of services we provide.” Craig Morley, Global Managing Director of Millipore’s BioPharma Services added: “The new facility complements the outstanding facilities at our St. Charles site and is a significant milestone in our development as “The World’s Large Molecule Lab.”
Additional Resources For more information, visit www.millipore.com or www.bioanalab.com.
About Millipore
Millipore (NYSE: MIL) is a life science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,000 employees worldwide. For more information, visit www.millipore.com.
ADVANCING LIFE SCIENCE TOGETHER® Research, Development, Production
Millipore Media Contact Greg Hoff Media Relations Bioscience Division 978-762-5170 greg_hoff@millipore.com
